

Cristina Festari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903146/publications.pdf>

Version: 2024-02-01

23
papers

1,799
citations

516710

16
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

2674
citing authors

#	ARTICLE	IF	CITATIONS
1	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	6.4	22
2	Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. <i>European Journal of Neurology</i> , 2020, 27, 475-483.	3.3	20
3	The A/T/N model applied through imaging biomarkers in a memory clinic. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 247-255.	6.4	23
4	Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 683-697.	2.6	183
5	Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples. <i>Frontiers in Microbiology</i> , 2020, 11, 1262.	3.5	36
6	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 414-421.	0.7	5
7	Medial temporal lobe atrophy and posterior atrophy scales normative values. <i>NeuroImage: Clinical</i> , 2019, 24, 101936.	2.7	12
8	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. <i>Alzheimer's and Dementia</i> , 2018, 14, 1088-1098.	0.8	15
9	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1557-1566.	6.4	35
10	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1470-1486.	6.4	19
11	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1546-1556.	6.4	24
12	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508.	6.4	61
13	P4064: THE EFFECT OF APOE ON WHITE MATTER LESIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1457.	0.8	0
14	ICP071: THE EFFECT OF APOE ON WHITE MATTER LESIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P63.	0.8	1
15	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1534-1545.	6.4	86
16	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1487-1496.	6.4	35
17	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	3.3	153
18	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	6.4	81

#	ARTICLE	IF	CITATIONS
19	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1526-1533.	6.4	28
20	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. <i>Neurobiology of Aging</i> , 2017, 49, 60-68.	3.1	870
21	The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the india-FBP study. <i>Neurobiology of Aging</i> , 2016, 39, S27.	3.1	0
22	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 1417.	9.0	84
23	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. <i>Neurodegenerative Diseases</i> , 2016, 16, 111-117.	1.4	6